Has Nitin Malik, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,793 in general payments to Nitin Malik, MD across 24 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nitin Malik, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nitin Malik, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nitin Malik, MD

Cardiovascular Disease · New York, NYNPI 1912360306

Payments from drug & device makers

$2,793in general payments, 2019–2025

Across 24 payments — averaging $116.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$2K
Philips North America LLC$263
Heartflow, Inc.$40
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38
Edwards Lifesciences$23
Amgen$19

What the payments were for

Travel & lodging$2,04073%
Food & beverage$75327%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	17	$2,411
Philips North America LLC	2	$263
Heartflow, Inc.	1	$40
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$38
Edwards Lifesciences	1	$23
Amgen	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TRICLIP$1,929
EPIQ 7C$238

How this compares

$2,793 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$74,926

Medicare patients

706

Services billed

1,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	33	$30,956
Atorvastatin Calcium	57	$859
Metoprolol Succinate	56	$783
Rosuvastatin Calcium	17	$398
Amlodipine Besylate	24	$225
Lisinopril	18	$206
Carvedilol	17	$156
Torsemide	18	$154
Nitroglycerin	13	$136
Isosorbide Mononitrate ErIsosorbide Mononitrate	15	$135

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

James MinNew York$41.1M
Robert RosensonNew York$6.9M
Roxana MehranNew York$6.4M
Roger HajjarNew York$5.2M
Philippe GenereuxNew York$4.4M
Gregg StoneNew York$3.7M
Valentin FusterNew York$2.9M
Tamim NazifNew York$2.2M
Howard WeintraubNew York$1.7M
Anuradha Lala-TrindadeNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →